Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
2000 1
2001 2
2002 2
2003 3
2004 1
2005 2
2006 5
2007 4
2008 6
2009 7
2010 1
2011 3
2012 6
2013 1
2014 3
2015 8
2016 7
2017 9
2018 11
2019 8
2020 15
2021 8
2022 6
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review.
Berends M, Nienhuis HLA, Adams D, Karam C, Luigetti M, Polydefkis M, Reilly MM, Sekijima Y, Hazenberg BPC. Berends M, et al. Among authors: polydefkis m. Int J Mol Sci. 2024 Mar 28;25(7):3770. doi: 10.3390/ijms25073770. Int J Mol Sci. 2024. PMID: 38612579 Free PMC article. Review.
Coexistence of Light Chain and Transthyretin Cardiac Amyloidosis.
Gami A, Woller J, Scheel P, Ali SA, Huff CA, Steenbergen C Jr, Halushka M, Sharma K, Polydefkis M, Vaishnav J. Gami A, et al. Among authors: polydefkis m. JACC Case Rep. 2024 Mar 5;29(7):102285. doi: 10.1016/j.jaccas.2024.102285. eCollection 2024 Apr 3. JACC Case Rep. 2024. PMID: 38465284 Free PMC article.
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
Ticau S, Aldinc E, Polydefkis M, Adams D, Coelho T, Ueda M, Hale C, Vest J, Nioi P; Patisiran Global OLE Collaborators. Ticau S, et al. Among authors: polydefkis m. Amyloid. 2024 Mar;31(1):1-11. doi: 10.1080/13506129.2023.2232520. Epub 2023 Jul 20. Amyloid. 2024. PMID: 37469249 Clinical Trial.
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
Brannagan TH, Coelho T, Wang AK, Polydefkis MJ, Dyck PJ, Berk JL, Drachman B, Gorevic P, Whelan C, Conceição I, Plante-Bordeneuve V, Merlini G, Obici L, Plana JMC, Gamez J, Kristen AV, Mazzeo A, Gentile L, Narayana A, Olugemo K, Aquino P, Benson MD, Gertz M; NEURO-T. T. R. Open-Label Extension Investigators. Brannagan TH, et al. Among authors: polydefkis mj. J Neurol. 2022 Dec;269(12):6416-6427. doi: 10.1007/s00415-022-11276-8. Epub 2022 Jul 31. J Neurol. 2022. PMID: 35908242 Free PMC article.
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Adams D, et al. Among authors: polydefkis m. Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23. Amyloid. 2023. PMID: 35875890 Clinical Trial.
Neuropathic symptoms with SARS-CoV-2 vaccination.
Safavi F, Gustafson L, Walitt B, Lehky T, Dehbashi S, Wiebold A, Mina Y, Shin S, Pan B, Polydefkis M, Oaklander AL, Nath A. Safavi F, et al. Among authors: polydefkis m. medRxiv [Preprint]. 2022 May 17:2022.05.16.22274439. doi: 10.1101/2022.05.16.22274439. medRxiv. 2022. PMID: 35611338 Free PMC article. Preprint.
111 results